Trial Profile
A pilot clinical trial to evaluate the biological activity of fulvestrant (Faslodex) in breast ductal carcinoma (DCIS)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary) ; Tamoxifen
- Indications Ductal carcinoma; Early breast cancer
- Focus Therapeutic Use
- 21 Aug 2006 Status change
- 09 Feb 2006 New trial record.